ArticleJournal for immunotherapy of cancer2021
CXCR6 is required for antitumor efficacy of intratumoral CD8
Article in Journal for immunotherapy of cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 77 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
77 citing papers in PubMed, 100 citations in OpenAlex.
- Multifaceted roles of chemokines in gastric cancer: From tumor microenvironment modulation to therapeutic targeting (Review).Oncology letters · 2026Review
- IL-23-engineered oncolytic vaccinia virus enhances pancreatic cancer control through inflammasome-driven Th17-skewed CD4Journal for immunotherapy of cancer · 2026Article
- Cardiac tertiary immune niches drive immune activation in immune checkpoint inhibitor myocarditis.Science advances · 2026Article
- A dual pronged approach to cancer immune exclusion: tumor-derived LAIR-1 simultaneously drives fibrosis and blocks immune recruitment in glioma.Research square · 2026Article
- Epithelial-mesenchymal transition is associated with altered immune composition and cytotoxic function in triple-negative breast cancer.Breast cancer research : BCR · 2026Article
- Clonal expansion and phenotypic alterations of TCR Vβ3Journal of virology · 2026Article
- HBV-driven expansion of CXCR6Innovation (Cambridge (Mass.)) · 2026Article
- Glycolysis-driven cancer-associated fibroblasts shape T-Cell exclusion via the CXCL16-CXCR6 Axis: a metabolic-chemokine mechanism in tumor immunity.Journal of translational medicine · 2026Review
- CCL5 hiCD4+ T Cells Regulate Macrophage Polarization and Promote Immunotherapy Response in Bladder Cancer.Cancer research · 2026Article
- Chemokine-chemokine receptor axis: Emerging immunotherapeutic paradigms for solid tumor microenvironment reprogramming.Chinese medical journal · 2026Review
- Integrated analysis identifies a CXCR6/CD45/PD-1-based risk model for melanoma prognosis and intratumoral CD8+/CD69 + T-cell infiltration correlation.Cellular oncology (Dordrecht, Netherlands) · 2026Article
- Dual regulation of CXCR6Journal for immunotherapy of cancer · 2026Article
- CXCR6Circulation · 2026Article
- Triple targeting of STING, TGF-β, and PD-L1 boosts CXCL16-CXCR6 signaling for potent antitumor response.Nature communications · 2026Article
- Article
- Single-cell dissection of hepatocellular carcinoma immunity: from heterogeneous subtypes to precision therapeutics.Frontiers in immunology · 2026Review
- Plantaricin BM-1 enhances anti-colorectal cancer effects by inhibiting CD8+ cytotoxic T cell apoptosis via the ERK/AP1/Bim signaling pathway.Frontiers in immunology · 2026Article
- Identification of a neoplastic Tfh-like cellular subset in a mouse model of angioimmunoblastic T cell lymphoma.Frontiers in oncology · 2026Article
- Advancements in understanding and treating CXCL16/CXCR6 in tumors and in inflammatory diseases: a narrative review.Frontiers in immunology · 2026Review
- Cellular dynamics in cerebrospinal fluid unveils the key regulators of intracranial response to immune checkpoint inhibitors in NSCLC brain metastases.Journal for immunotherapy of cancer · 2025Article
17 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
12 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIncreasing infiltration of CD8
methodsCombination of single-cell RNA sequencing, general transcriptome sequencing data and multiparametric cytometric techniques allowed us to map CXCR6 expression on specific cell type and tissue. We applied
resultsWe identified that CXCR6 was exclusively expressed on intratumoral CD8
conclusionsThis study may contribute to the rational design of combined immunotherapy. Alternatively, CXCR6 may be used as a biomarker for effective CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.